Enigma Prevents Cbl-c-Mediated Ubiquitination and Degradation of RETMEN2A
Open Access
- 23 January 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (1) , e87116
Abstract
The Cbl proteins (Cbl, Cbl-b, and Cbl-c) are a highly conserved family of RING finger ubiquitin ligases (E3s) that function as negative regulators of tyrosine kinases in a wide variety of signal transduction pathways. In this study, we identify a new Cbl-c interacting protein, Enigma (PDLIM7). This interaction is specific to Cbl-c as Enigma fails to bind either of its closely related homologues, Cbl and Cbl-b. The binding between Enigma and Cbl-c is mediated through the LIM domains of Enigma as removal of all three LIM domains abrogates this interaction, while only LIM1 is sufficient for binding. Here we show that Cbl-c binds wild-type and MEN2A isoforms of the receptor tyrosine kinase, RET, and that Cbl-c enhances ubiquitination and degradation of activated RET. Enigma blocks Cbl-c-mediated RETMEN2A ubiquitination and degradation. Cbl-c decreased downstream ERK activation by RETMEN2A and co-expression of Enigma blocked the Cbl-c-mediated decrease in ERK activation. Enigma showed no detectable effect on Cbl-c-mediated ubiquitination of activated EGFR suggesting that this effect is specific to RET. Through mapping studies, we show that Cbl-c and Enigma bind RETMEN2A at different residues. However, binding of Enigma to RETMENA prevents Cbl-c recruitment to RETMEN2A. Consistent with these biochemical data, exploratory analyses of breast cancer patients with high expression of RET suggest that high expression of Cbl-c correlates with a good outcome, and high expression of Enigma correlates with a poor outcome. Together, these data demonstrate that Cbl-c can ubiquitinate and downregulate RETMEN2A and implicate Enigma as a positive regulator of RETMEN2A through blocking of Cbl-mediated ubiquitination and degradation.Keywords
This publication has 49 references indexed in Scilit:
- Cbl-c Ubiquitin Ligase Activity Is Increased via the Interaction of Its RING Finger Domain with a LIM Domain of the Paxillin Homolog, Hic 5PLOS ONE, 2012
- Alternative splicing results in RET isoforms with distinct trafficking propertiesMolecular Biology of the Cell, 2012
- The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cellsBreast Cancer Research and Treatment, 2011
- RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesisNature Reviews Cancer, 2011
- A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast CancerJAMA, 2011
- Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimizationBMC Cancer, 2011
- Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in miceJournal of Clinical Investigation, 2010
- EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteinsOncogene, 2006
- The Cbl interactome and its functionsNature Reviews Molecular Cell Biology, 2005
- Distinct Turnover of Alternatively Spliced Isoforms of the RET Kinase Receptor Mediated by Differential Recruitment of the Cbl Ubiquitin LigaseJournal of Biological Chemistry, 2005